US 9,808,481 B2
Prebiotic formulations and methods of use
Andrew J. Ritter, Los Angeles, CA (US); Dennis Savaiano, West Lafayette, IN (US); David Barnes, Dexter, MI (US); and Todd Klaenhammer, Raleigh, NC (US)
Assigned to Ritter Pharmaceuticals, Inc., Los Angeles, CA (US)
Filed by Ritter Pharmaceuticals, Inc., Los Angeles, CA (US)
Filed on Jun. 20, 2016, as Appl. No. 15/187,576.
Application 15/187,576 is a continuation of application No. 14/485,301, filed on Sep. 12, 2014, granted, now 9,370,532.
Application 14/485,301 is a continuation of application No. 13/770,750, filed on Feb. 19, 2013, abandoned.
Application 13/770,750 is a continuation of application No. 12/707,037, filed on Feb. 17, 2010, granted, now 8,492,124, issued on Jul. 23, 2013.
Claims priority of provisional application 61/272,622, filed on Oct. 13, 2009.
Claims priority of provisional application 61/155,150, filed on Feb. 24, 2009.
Prior Publication US 2016/0367579 A1, Dec. 22, 2016
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/702 (2006.01); A61K 31/715 (2006.01); A61K 35/745 (2015.01); A61K 35/747 (2015.01); A61K 31/7016 (2006.01); A61K 35/741 (2015.01); A61K 9/48 (2006.01); A23L 33/21 (2016.01); A23L 33/135 (2016.01); A61K 31/7004 (2006.01)
CPC A61K 31/715 (2013.01) [A23L 33/135 (2016.08); A23L 33/21 (2016.08); A61K 9/4825 (2013.01); A61K 31/702 (2013.01); A61K 31/7004 (2013.01); A61K 31/7016 (2013.01); A61K 35/741 (2013.01); A61K 35/745 (2013.01); A61K 35/747 (2013.01); A23V 2002/00 (2013.01); A23Y 2220/00 (2013.01); A23Y 2300/00 (2013.01)] 17 Claims
 
1. A pharmaceutical composition comprising: a GOS composition comprising at least 95% by weight galactooligosaccharides (GOS) and 5% or less by weight digestible saccharides, wherein the GOS composition comprises about 5-25% pentasaccharides.